Recce Pharmaceuticals
recce.com.au
ACN 124 849 065

ASX Announcement

1 July 2026

Cleansing notice under section 708A(5)(e) of the Corporations Act

This notice is being given by Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**). The Company has today issued a total of 10,135,399 fully paid ordinary shares (**Shares**) comprising of:

1. 9,850,000 Shares issued at an issue price of $0.40 per Share to sophisticated and professional investors under a placement announced on 26 June 2026;
2. 250,000 Shares issued at a deemed issue price of $0.40 per Share to SP Corporate Advisory Pty Ltd in lieu of cash fees as consideration for investor relations services; and
3. 35,399 Shares issued to an employee pursuant to the terms of an employment contract.

For the purposes of section 708A(6) of the Corporations Act, the Company advises that:

(a) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

(b) this notice is being given under section 708A(5)(e) of the Corporations Act;

(c) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:

   i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   ii. sections 674 and 674A of the Corporations Act; and

(d) as at the date of this notice, there is no information that is 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act, which is required to be disclosed by the Company.

The Appendix 2A's relating to the issue of Shares noted above have been released to ASX prior to this announcement.

For further information, please contact:

Maggie Niewidok
Company Secretary
company.secretary@recce.com.au

This announcement has been approved for release by Recce Pharmaceuticals Board.